Trials / Unknown
UnknownNCT02743065
HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter registry is to gather the safety, efficacy and survival data in advanced HCC patients treated with HepaSphere in China in order to evaluate the application of HepaSphere deTACE in treating advanced HCC patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | HepaSphere with 50-75mg Doxorubicin | HepaSphere with 50-75mg Doxorubicin |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2019-06-01
- Completion
- 2019-12-01
- First posted
- 2016-04-19
- Last updated
- 2018-09-20
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02743065. Inclusion in this directory is not an endorsement.